Asthma L-Citrulline Pilot Study

Exclusion Criteria

• •Respiratory tract infection within the 4 weeks prior to the study (may re-enroll after 4 weeks).
• •Oral or systemic corticosteroid burst (for any indication) within the 4 weeks
• •One-time doses, such as intra-articular injections into a shoulder or knee joint, require a 2-week washout.
• •Asthma-related ER visit within the previous 4 weeks of Visit 1
• •Significant concomitant medical illness, including (but not limited to)
• •* Heart disease
• •* Cancer
• •* Uncontrolled diabetes,
• •Chronic renal failure (creatinine \> 2.0) at Visit 1 (Associated with higher ADMA levels)
• •Untreated sleep apnea
• •Other chronic lung/respiratory diseases (COPD, IPF, etc.)
• •High dose inhaled steroids (\> 1000 mcg/day of Fluticasone or equivalent)
• •Current statin use (statins lower ADMA levels); patients may stop statins with approval from their primary physician and enroll after a 6-week washout
• •Positive urine pregnancy test at Visit 1 or at any time during the study
• •Intolerance or allergy to L-arginine or L-citrulline
• •Concomitant use of PDE5 drugs or oral mononitrates
• •Participation in an intervention study, use of investigative drugs within the past 30 days or plans to enroll in such a trial during the study
• •Unable or unlikely to complete study assessments in the opinion of the Investigator
• •Study intervention poses undue risk to patient in the opinion of the Investigator
• •Breastfeeding